Maise M. Dias

Belo Horizonte, MG, Brazil

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Corrigendum to 'Deleterious variants cluster in the A3 domain of factor VIII in people with severe hemophilia A and inhibitors': [Research and Practice in Thrombosis and Haemostasis Volume 9, Issue 6, August 2025, 103006].

Corrigendum to 'Deleterious variants cluster in the A3 domain of factor VIII in people with severe hemophilia A and inhibitors': [Research and Practice in Thrombosis and Haemostasis Volume 9, Issue 6, August 2025, 103006].

Journal: Research and practice in thrombosis and haemostasis

Published: February 18, 2026

Deleterious variants cluster in the A3 domain of factor VIII in people with severe hemophilia A and inhibitors.

Deleterious variants cluster in the A3 domain of factor VIII in people with severe hemophilia A and inhibitors.

Journal: Research and practice in thrombosis and haemostasis

Published: May 12, 2025

Genomic ancestry, F8 variants, and immune tolerance in hemophilia A patients with inhibitors: exome sequencing insights.

Genomic ancestry, F8 variants, and immune tolerance in hemophilia A patients with inhibitors: exome sequencing insights.

Journal: Haematologica

Published: December 20, 2024

Cost of immune tolerance induction according to its outcome in people with hemophilia A and inhibitors: results from the Co$tIT study.

Cost of immune tolerance induction according to its outcome in people with hemophilia A and inhibitors: results from the Co$tIT study.

Journal: Thrombosis research

Published: October 14, 2024

Large deletions and small insertions and deletions in the factor VIII gene predict unfavorable immune tolerance induction outcome in people with severe hemophilia A and high-responding inhibitors.

Large deletions and small insertions and deletions in the factor VIII gene predict unfavorable immune tolerance induction outcome in people with severe hemophilia A and high-responding inhibitors.

Journal: Thrombosis research

Published: May 11, 2024

High levels of anti-factor VIII immunoglobulin G4 and immunoglobulin G total are associated with immune tolerance induction failure in people with congenital hemophilia A and high-responding inhibitors.

High levels of anti-factor VIII immunoglobulin G4 and immunoglobulin G total are associated with immune tolerance induction failure in people with congenital hemophilia A and high-responding inhibitors.

Journal: Research and practice in thrombosis and haemostasis

Published: March 25, 2024

Minor surgical procedures during immune tolerance induction in people with hemophilia A and inhibitors: results from the Brazilian Immune Tolerance (BrazIT) study cohort.

Minor surgical procedures during immune tolerance induction in people with hemophilia A and inhibitors: results from the Brazilian Immune Tolerance (BrazIT) study cohort.

Journal: Hematology, transfusion and cell therapy

Published: February 20, 2024

Changing recombinant factor VIII to plasma-derived factor VIII during immune tolerance induction.

Changing recombinant factor VIII to plasma-derived factor VIII during immune tolerance induction.

Journal: Pediatric hematology and oncology

Published: February 24, 2023

Time between inhibitor detection and start of immune tolerance induction: Association with outcome in the BrazIT study.

Time between inhibitor detection and start of immune tolerance induction: Association with outcome in the BrazIT study.

Journal: Journal of thrombosis and haemostasis : JTH

Published: May 13, 2022

Showing 1-9 of 9

Last Updated: 09/26/2026